文献速递胃肠动力与功能性疾病

普瑞巴林治疗功能性消化不良的随机对照试验

Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia.
PubMed 文献 · Aliment Pharmacol Ther · 2021-08-30

本研究为随机安慰剂对照试验,纳入质子泵抑制剂无效的功能性消化不良患者,普瑞巴林75mg每日一次治疗8周。第4周和第8周 adequate relief 率普瑞巴林组均显著高于安慰剂组,全球症状评分改善更明显,生活质量改善,但头晕发生率51.6%。

要点

  • 普瑞巴林75mg每日一次可显著提高PPI无效FD患者的 adequate relief 率。
  • 普瑞巴林对以餐后上腹痛为主的患者症状缓解更明显。
  • 最常见不良事件为头晕,发生率51.6%。

核心结论

  • 普瑞巴林可显著缓解功能性消化不良症状,尤其对以餐后上腹痛为主的患者。

研究设计与样本

  • 随机安慰剂对照研究,纳入PPI无效的功能性消化不良患者72例,普瑞巴林组34例,安慰剂组38例,治疗8周。

主要发现

  • 第4周 adequate relief 率普瑞巴林组70.6% vs 安慰剂组42.1%(P=0.02)。
  • 第8周 adequate relief 率普瑞巴林组70.6% vs 安慰剂组44.7%(P=0.03)。
  • 第4周全球症状评分下降普瑞巴林组11.7±10.6分 vs 安慰剂组3.7±8.9分(P<0.01)。
  • 第8周全球症状评分下降普瑞巴林组15.1±12.2分 vs 安慰剂组8.0±10.2分(P=0.01)。
  • 普瑞巴林改善整体生活质量(P=0.03)。

关键数值与推荐

  • 普瑞巴林剂量为75mg每日一次,疗程8周。
  • 最常见不良事件为头晕,发生率51.6%。

临床怎么用

  • 对于PPI无效的功能性消化不良患者,尤其是以餐后上腹痛为主者,可考虑使用普瑞巴林75mg每日一次治疗8周。
  • 使用普瑞巴林时需注意头晕等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently, central neuromodulators are among the therapeutic options for the treatment of functional dyspepsia (FD). Pregabalin, a gabapentinoid, is a neuromodulator that could potentially improve visceral hypersensitivity in FD patients. AIM: To assess the efficacy and safety of pregabalin for the treatment of FD METHODS: We performed a randomised placebo-controlled study including FD patients who did not respond to proton pump inhibitors. Patients were randomly assigned to receive pregabalin (75 mg daily) or placebo for 8 weeks. The primary outcome was an adequate relief response rate. The secondary outcomes were improvement in quality of life, pain scores in divided categories, and safety profile. RESULTS: Of 72 patients enrolled, 34 received pregabalin and 38 received placebo. The self-reported adequate relief rates in the pregabalin and placebo groups were 70.6% and 42.1% at week 4 (P = 0.02), and 70.6% and 44.7% at week 8 (P = 0.03), respectively. The reduction in global symptoms in the pregabalin and placebo groups were 11.7 ± 10.6 and 3.7 ± 8.9 points at week 4 (P < 0.01) and 15.1 ± 12.2 and 8.0 ± 10.2 points at week 8 (P = 0.01), respectively. Pregabalin improved the overall quality of life (P = 0.03). The most common adverse event with pregabalin was dizziness, occurring in 51.6% of patients. CONCLUSIONS: Pregabalin led to significant alleviation of dyspeptic symptoms, especially in patients with predominant epigastric pain . Thaiclinicaltrials.org #TCTR20200404002.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kotikula I, Thinrungroj N, Pinyopornpanish K, et al. Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia. Aliment Pharmacol Ther. 2021. PMID: 34460973. doi:10.1111/apt.16588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。